Tirzepatide
SURMOUNT-OSA
Eli Lilly · Phase 3 · Completed · Enrollment 469
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Tirzepatide MTD_GPI1 | Obesity or overweight | n/r | 52 | n/r | n/r |
| Placebo_GPI1 | Obesity or overweight | n/r | 52 | n/r | n/r |
| Tirzepatide MTD_GPI2 | Obesity or overweight | n/r | 52 | n/r | n/r |
| Placebo_GPI2 | Obesity or overweight | n/r | 52 | n/r | n/r |